Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Urovant Sciences Ltd (UROV)

Urovant Sciences Ltd (UROV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 531,746
  • Shares Outstanding, K 32,743
  • Annual Sales, $ 0 K
  • Annual Income, $ -146,750 K
  • 60-Month Beta 2.35
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade UROV with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.14
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/11/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -2.27
  • Number of Estimates 2
  • High Estimate -1.93
  • Low Estimate -2.61
  • Prior Year -1.57
  • Growth Rate Est. (year over year) -44.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.10 +0.84%
on 03/02/21
16.26 -0.12%
on 03/19/21
+0.07 (+0.43%)
since 02/26/21
3-Month
16.03 +1.31%
on 12/30/20
16.26 -0.12%
on 03/19/21
+0.20 (+1.25%)
since 12/24/20
52-Week
7.15 +127.13%
on 11/02/20
16.26 -0.12%
on 03/19/21
+6.09 (+60.00%)
since 03/26/20

Most Recent Stories

More News
Hercules Capital Reports Fourth Quarter and Full-Year 2020 Financial Results

--Q4 2020 Net Investment Income Provides 116% Coverage of Base Distribution Payout

DASH : 149.46 (+1.10%)
MASS : 52.31 (+3.03%)
ACEV : 9.98 (+0.40%)
ASPL : 10.02 (-0.10%)
ACTC : 16.36 (+0.37%)
PACE : 10.05 (+0.10%)
UBER : 60.64 (+2.02%)
UROV : 16.24 (+0.06%)
NEOS : 1.1500 (-2.54%)
AYTU : 6.75 (-1.32%)
HTGC : 16.90 (-0.41%)
HCXZ : 25.54 (-0.08%)
HCXY : 27.09 (+0.89%)
STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger

NEW YORK, NY / ACCESSWIRE / February 19, 2021 / , founder and managing partner at , a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered...

MGLN : 94.35 (+0.52%)
RP : 87.75 (-0.09%)
UROV : 16.24 (+0.06%)
NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: Urovant Sciences Ltd. (Nasdaq - UROV), Cubic Corporation (NYSE - CUB), CoreLogic, Inc. (NYSE - CLGX)

BALA CYNWYD, PA / ACCESSWIRE / February 13, 2021 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and...

UROV : 16.24 (+0.06%)
CUB : 74.82 (-0.11%)
CLGX : 79.72 (+0.06%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, NHLD, COHR, UROV; Shareholders Are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

MDCA : 3.55 (-5.33%)
NHLD : 3.25 (unch)
COHR : 266.73 (-0.22%)
UROV : 16.24 (+0.06%)
Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders Are Encouraged to Contact the Firm - CPAH, UROV, ANH, CGIX, CBLI, NEOS

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

CPAH : 3.48 (+0.58%)
UROV : 16.24 (+0.06%)
ANH : 2.98 (+0.34%)
CGIX : 4.61 (-2.33%)
CBLI : 6.95 (+19.83%)
NEOS : 1.1500 (-2.54%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds JWS, BRPA, and UROV Shareholders About Its Ongoing Investigations

, /PRNewswire/ --

JWS : 13.15 (+0.84%)
BRPA : 33.09 (-6.42%)
UROV : 16.24 (+0.06%)
Lifshitz Law Firm, P.C. Announces Investigation of CBMG, CIT, HMSY, INFO, PS, SPWH, UROV, and WDR

, /PRNewswire/ --

CBMG : 19.75 (unch)
CIT : 50.17 (-4.22%)
HMSY : 36.97 (unch)
INFO : 102.71 (+0.38%)
PS : 22.45 (+0.13%)
SPWH : 17.54 (-0.40%)
UROV : 16.24 (+0.06%)
WDR : 24.95 (unch)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates COHR, CBMG, WTRE, NAV, UROV; Shareholders Are Encouraged to Contact the Firm

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

COHR : 266.73 (-0.22%)
CBMG : 19.75 (unch)
WTRE : 34.85 (-0.06%)
NAV : 44.20 (+0.07%)
UROV : 16.24 (+0.06%)
Lifshitz Law Firm, P.C. Announces Investigation of CBMG, HMSY, UROV, and WDR

NEW YORK, NY / ACCESSWIRE / January 18, 2021 / Lifshitz Law Firm, P.C.:

CBMG : 19.75 (unch)
HMSY : 36.97 (unch)
UROV : 16.24 (+0.06%)
WDR : 24.95 (unch)
ALERT: Halper Sadeh LLP Reminds Investors of Its Ongoing Merger Investigations; Shareholders are Encouraged to Contact the Firm - CBMG, CGIX, UROV

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

CBMG : 19.75 (unch)
CGIX : 4.61 (-2.33%)
UROV : 16.24 (+0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international...

See More

Key Turning Points

3rd Resistance Point 16.28
2nd Resistance Point 16.26
1st Resistance Point 16.25
Last Price 16.24
1st Support Level 16.22
2nd Support Level 16.20
3rd Support Level 16.19

See More

52-Week High 16.26
Last Price 16.24
Fibonacci 61.8% 12.78
Fibonacci 50% 11.70
Fibonacci 38.2% 10.63
52-Week Low 7.15

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar